Cargando…

The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis

BACKGROUND: The circulating tumor DNA (ctDNA) diagnostic accuracy for detecting phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations in breast cancer (BC) is under discussion. We aimed to compare plasma and tissue PIK3CA alterations, encompassing factors that cou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Galvano, Antonio, Castellana, Luisa, Gristina, Valerio, La Mantia, Maria, Insalaco, Lavinia, Barraco, Nadia, Perez, Alessandro, Cutaia, Sofia, Calò, Valentina, Bazan Russo, Tancredi Didier, Francini, Edoardo, Incorvaia, Lorena, Mirisola, Mario Giuseppe, Vieni, Salvatore, Rolfo, Christian, Bazan, Viviana, Russo, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516428/ https://www.ncbi.nlm.nih.gov/pubmed/36188485 http://dx.doi.org/10.1177/17588359221110162

Ejemplares similares

Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study
por: Gristina, Valerio, et al.
Publicado: (2022)

Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
por: Incorvaia, Lorena, et al.
Publicado: (2019)

Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses
por: Gristina, Valerio, et al.
Publicado: (2021)

Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—a trial-level meta-analysis in PD-L1 selected subgroups
por: Passiglia, Francesco, et al.
Publicado: (2021)

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
por: Gristina, Valerio, et al.
Publicado: (2020)

How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis
por: Galvano, Antonio, et al.
Publicado: (2019)

Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors
por: Dimino, Alessandra, et al.
Publicado: (2022)

Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1
por: Badalamenti, Giuseppe, et al.
Publicado: (2019)

Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay
por: Incorvaia, Lorena, et al.
Publicado: (2023)

“Back to a false normality”: new intriguing mechanisms of resistance to PARP inhibitors
por: Incorvaia, Lorena, et al.
Publicado: (2016)

Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily)—Prevalence and Geographic Distribution of Pathogenic Variants in BRCA1/2 Genes
por: Incorvaia, Lorena, et al.
Publicado: (2020)

Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?
por: Fanale, Daniele, et al.
Publicado: (2016)

BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients
por: Incorvaia, Lorena, et al.
Publicado: (2020)

Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer
por: Listì, Angela, et al.
Publicado: (2019)

Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials
por: Galvano, Antonio, et al.
Publicado: (2019)

The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials
por: Galvano, A., et al.
Publicado: (2021)

Safety and effectiveness of gemcitabine for the treatment of classic Kaposi’s sarcoma without visceral involvement
por: Badalamenti, Giuseppe, et al.
Publicado: (2022)

Impact of Different Selection Approaches for Identifying Lynch Syndrome-Related Colorectal Cancer Patients: Unity Is Strength
por: Fanale, Daniele, et al.
Publicado: (2022)

Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis
por: Galvano, Antonio, et al.
Publicado: (2019)

Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2
por: Fanale, Daniele, et al.
Publicado: (2020)

Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab
por: Incorvaia, Lorena, et al.
Publicado: (2023)

Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score
por: Galvano, Antonio, et al.
Publicado: (2020)

Moving the Target on the Optimal Adjuvant Strategy for Resected Pancreatic Cancers: A Systematic Review with Meta-Analysis
por: Galvano, Antonio, et al.
Publicado: (2020)

Immunological Aspects of Von Hippel-Lindau Disease: A Focus on Neuro-Oncology and Myasthenia Gravis
por: Norata, Davide, et al.
Publicado: (2023)

Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients
por: Passiglia, Francesco, et al.
Publicado: (2019)

Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer?
por: Fanale, Daniele, et al.
Publicado: (2022)

Reply to: Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials (Galvano et al., J Bone Oncol 2019; 18:100252)
por: Galvano, Antonio, et al.
Publicado: (2020)

Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway
por: Massihnia, Daniela, et al.
Publicado: (2016)

Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer
por: Fanale, Daniele, et al.
Publicado: (2023)

Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus
por: Cabibi, Daniela, et al.
Publicado: (2016)

A narrative review on the implementation of liquid biopsy as a diagnostic tool in thoracic tumors during the COVID-19 pandemic
por: Pisapia, Pasquale, et al.
Publicado: (2021)

PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
por: Passiglia, Francesco, et al.
Publicado: (2016)

Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma
por: Incorvaia, Lorena, et al.
Publicado: (2016)

New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?
por: Bronte, Giuseppe, et al.
Publicado: (2015)

One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients
por: Badalamenti, Giuseppe, et al.
Publicado: (2019)

Analysis of miRNA expression profile induced by short term starvation in breast cancer cells treated with doxorubicin
por: Rizzo, Sergio, et al.
Publicado: (2017)

Hypoxia and Human Genome Stability: Downregulation of BRCA2 Expression in Breast Cancer Cell Lines
por: Fanale, Daniele, et al.
Publicado: (2013)

Longevity: Lesson from Model Organisms
por: Taormina, Giusi, et al.
Publicado: (2019)

MicroRNAs in colorectal cancer stem cells: new regulators of cancer stemness?
por: Caruso, S, et al.
Publicado: (2012)

Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells
por: Insalaco, Lavinia, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_r9jel27uk7hpr6ocma3b8hs0r9